Loading…

MedCap ABMCAP.STCompetitor analysis, valuation and peers

Sweden · SEK·Health Care›Medical Specialties
Momentum weak 36
Mkt cap
$811M
US dollars, full cap
Free float
79%
of shares outstanding
$/day
$1.58M
20-day average traded
Fwd P/E
25.8×
forward earnings
ROIC−WACC
+9.2 pp
WACC 5.3%
Hurdle
-18 pp
Req g minus delivered
Next earnings
79 days
5 Feb 2027
Close · SEKSEK 547.00
1D0.0%
1W-0.5%
1M+1.4%
3M-3.4%
6M-4.1%
YTD-0.4%
1Y+1.1%
ATR %2.8%
52w lowhigh9.5% off high

What MedCap does

Employees: 637

MedCap at a glance

Size MedCap (MCAP.ST) is a Sweden Health Care company (Medical Specialties) with a market value of $811M, the 143rd largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 547.00 on 18 Nov 2026.

Performance Over six months the shares fell 4.1%, against -15.2% for the median peer and +2.8% for the Sweden market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 16.5% over the last twelve months (peer median +6.2%); the operating margin is 14.7% (peer median 9.4%).

Valuation It trades at 25.8× forward earnings against a peer median of 19.9× (3rd most expensive of 13).

Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is -18 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 9.2 points above its cost of capital (5.3% WACC).

Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 2026MCAP.ST 97Peer median 86
Six months, rebased to 100: MedCap against the median of its 20 peers (local-currency closes).

MedCap financials

Reported figures in SEK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueSEK 2.32BSEK 2.11BSEK 1.81BSEK 1.59BSEK 1.11B
Revenue growth—+17%+14%+43%—
Gross profitSEK 341MSEK 321MSEK 258MSEK 236MSEK 165M
EBITDASEK 528MSEK 433MSEK 346MSEK 311MSEK 221M
Net incomeSEK 274MSEK 220MSEK 207MSEK 172MSEK 118M
Free cash flowSEK 397MSEK 317MSEK 318MSEK 206MSEK 59.2M
Capital expenditureSEK 68.9MSEK 62.2MSEK 66.2MSEK 39.3MSEK 44.3M
Total debtSEK 438MSEK 483MSEK 358MSEK 261MSEK 340M

Quarterly statements and history in the cockpit →

MedCap competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-20%-10%0%+10%AMS096530688068688805KIDS1187SETL6033673600BBNXMLABCTKB1302VREX2190301602688656002658300463MCAP.ST6-month return →1-month return →
Up and to the right = strong over both horizons. MedCap is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×AMS09653011876033673600MLAB2190688656002658300463MCAP.STRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. MedCap is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%AMS09653068880511876033673600MLAB13022190688656002658300463MCAP.STGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. MedCap is the large dot.

MedCap competitors and peer comparison

How MedCap compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

MedCap against its 20 peers (data as of 18 Nov 2026)
MeasureMCAP.STPeer medianRank in peer set
1-month return+1.4%-5.1%6th highest of 21
6-month return-4.1%-15.2%9th highest of 21
Distance from 52-week high-9.5%-39.8%6th highest of 21
Revenue growth (TTM)+16.5%+6.2%6th highest of 21
Operating margin14.7%9.4%5th highest of 21
Forward P/E25.8×19.9×3rd most expensive of 13
Growth the price implies (Req g, 7 yrs)2.7%9.6%5th least demanding of 14
Growth delivered (Del g)+20.9%+11.3%3rd highest of 14
Hurdle (Req g minus delivered)-18.2 pp+6.5 pp3rd least demanding of 14
ROIC minus cost of capital+9.2 pp-1.9 pp3rd highest of 21
EV / EBITDA15.9×13.1×4th most expensive of 9
Net debt / EBITDA0.3×0.1×5th most indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
MedCap MCAP.STSweden$811M-4%+17%15%25.8×2.7%+20.9%
Advanced Medical Solutions AMS.LUnited Kingdom$811M+27%+6%12%20.7×20.0%+21.4%
Seegene 096530.KSSouth Korea$808M-26%+13%13%20.0×-6.7%-15.9%
Beijing Hotgen Biotech 688068.SSChina$815M-37%+8%-94%n/an/an/a
Ningbo Jansen Superconducting Technologies 688805.SSChina$818M-36%+36%16%n/a35.6%+17.1%
OrthoPediatrics KIDSUnited States$826M+71%+16%-8%n/an/an/a
Cofoe Medical Technology 1187.HKHong Kong$836M-11%+40%10%13.1×-6.4%+6.6%
Standard Engineering Technology SETL.NSIndia$783M+168%+45%14%n/an/an/a
Cisen Pharmaceutical 603367.SSChina$843M-15%-6%8%7.9×-14.6%-1.3%
Modern Dental 3600.HKHong Kong$844M+24%+12%22%8.5×-7.1%+11.3%
Beta Bionics BBNXUnited States$779M+42%+44%-73%n/an/an/a
Mesa Laboratories MLABUnited States$775M+33%+2%10%11.5×21.3%+13.2%
Cytek Biosciences CTKBUnited States$774M+57%+6%-21%n/an/an/a
LifeTech Scientific 1302.HKHong Kong$771M-30%+1%12%19.8×9.6%+15.5%
Varex Imaging VREXUnited States$771M+79%+5%8%19.9×n/an/a
Zylox-Tonbridge Medical Technology 2190.HKHong Kong$768M-16%+39%25%14.4×3.8%+105.8%
Shantou Institute of Ultrasonic Instruments 301602.SZChina$858M-25%+4%30%n/a11.1%+4.6%
HOB Biotech 688656.SSChina$858M-33%+6%7%166.9×37.6%+12.4%
Beijing SDL Technology 002658.SZChina$864M-34%-13%9%22.4×16.8%+2.9%
Maccura Biotechnology 300463.SZChina$756M-18%-1%-4%421.0×7.9%-10.2%
Tinavi Medical Technologies 688277.SSChina$872M-36%-2%-59%n/an/an/a

Questions

Which companies are MedCap's closest peers?
The cockpit's peer set: Advanced Medical Solutions (AMS.L), Seegene (096530.KS), Beijing Hotgen Biotech (688068.SS), Ningbo Jansen Superconducting Technologies (688805.SS), OrthoPediatrics (KIDS), Cofoe Medical Technology (1187.HK), Standard Engineering Technology (SETL.NS), Cisen Pharmaceutical (603367.SS).
Is MedCap expensive compared with its peers?
On forward p/e it trades at 25.8× against a peer median of 19.9×, 3rd most expensive of 13 in its peer set. For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is -18 pp: the price already allows for a slowdown.
How has MedCap stock performed?
Over six months to 18 Nov 2026 the shares returned -4.1% against -15.2% for the median peer; over one year +1.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.